Login / Signup

A Benefit/Risk Assessment of Intrathecal Ziconotide in Chronic Pain: A Narrative Review.

Emanuele RubiuFrancesco RestelliVittoria NazziElio MazzapicchiGiulio BonomoPierlorenzo VeiceschiTommaso AlfieroGianluca AgrestaDavide LocatelliAlessandro Dario
Published in: Journal of clinical medicine (2024)
Overall, the use of Ziconotide, as a monotherapy or in conjunction with other therapies for the treatment of chronic pain, was reported to be efficacious. Overall, its use in patients with chronic pain refractory to other pharmacologic agents outweighs the possible adverse consequences, thus resulting in a favorable benefit/risk assessment.
Keyphrases
  • chronic pain
  • risk assessment
  • pain management
  • human health
  • heavy metals
  • combination therapy
  • emergency department
  • open label
  • randomized controlled trial
  • replacement therapy
  • smoking cessation